The Angiogenesis Assay market is expected to grow from USD 1.81 Billion in 2020 to USD X.XX Billion by 2028, at a CAGR of 8.8% during the forecast period (2021-2028). The growth of this market can be attributed to factors such as the rising prevalence of cancer and other diseases that require the administration of drugs for their treatment which cause an increase in demand for angiogenesis assays, technological advancements in equipment used for performing these tests, and increased adoption rate of molecular diagnostic technologies among healthcare providers.

Angiogenesis is the process of formation of new blood vessels from pre-existing vasculature. It involves the proliferation, migration, and differentiation of endothelial cells which leads to increased vascularization. The angiogenesis assay market can be segmented by type (in vitro angiogenesis, in vivo angiogenesis), application (hospitals, clinics, others), and by region (North America, Latin America, Europe Asia Pacific, and the Middle East & Africa).

On the basis of types, the market is segmented into In Vitro Angiogenesis, and In Vivo Angiogenesis.

In Vitro Angiogenesis

In Vitro Angiogenesis is a process by which endothelial cells are cultured and stimulated to grow in the absence of any natural stimulus. This kind of angiogenesis has several applications for therapeutic purposes, including cancer treatment, cardiovascular therapies, etc. It can also be used in Cosmetic Procedures that include skin grafting or scar replacement treatments. Clinical trials are being conducted to assess the efficacy of In Vitro Angiogenesis in treating coronary artery disease.

In Vivo Angiogenesis

In vivo angiogenic assays are used for measuring vascularization, which is a key component of tumor growth and metastasis. This kind of assay uses special dyes that can be excited by light or fluorescence and emit blue, green, or red wavelengths of light. Tumor cells with high levels of vascularization can be stained more easily than those without it. It also helps to measure the areas of tumor growth and metastasis.

On the basis of application, the market is segmented into Hospitals and Clinics.

Hospitals

In Hospitals, the use of Angiogenesis Assay Market is used for early detection and diagnosis. In Hospitals, it provides information about which new treatment options are available to the patients depending on their specific disease condition or needs. It also enables the patients to assess their risk.

Clinics

In Clinics, it helps with early detection and diagnosis by looking at how blood flows through different tissues to identify abnormalities that can lead to disease or other medical conditions. It also provides guidance on which treatment options are available depending on specific disease conditions.

On the basis of region, the market is segmented into North America, Latin America, Europe, Asia Pacific, and Middle East & Africa.

North America is expected to hold the largest market share in 2019. The largest region in North America is the United States, which will have a high adoption rate of assays in hospitals and clinics. The presence of key players such as Agilent Technologies Inc., Thermo Fisher Scientific, R&D Systems Incorporated, Abcam Plc., Becton Dickinson & Company has led to significant growth in this region.

Growth factors of the Angiogenesis Assay Market

The growth factors of the market are as follows:

- Increasing number of research and development activities in this field.

- Rising R&D spending on cancer therapeutics.

- Increasing medical tourism in the Asia Pacific region

- Availability of government initiatives supporting research activities and product development.

Report Scope

Cancer Angiogenesis Inhibitors Market Outlook

The global cancer angiogenesis inhibitors market size is projected to grow from USD 9.5 billion in 2023 to USD 16.2 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 6.1% during the forecast period. The increasing prevalence of various types of cancers and advancements in biotechnology are significant growth factors driving this market. Cancer angiogenesis inhibitors are essential in cancer treatment as they block the formation of new blood vessels that tumors need to grow and metastasize, thus providing a targeted therapeutic approach.

One of the primary growth factors of the cancer angiogenesis inhibitors market is the rising incidence of cancer globally. With an aging population and lifestyle factors contributing to cancer risk, the demand for innovative and effective treatments is intensifying. Statistics indicate an upward trend in cancer diagnoses, thereby increasing the need for effective treatment regimens, including angiogenesis inhibitors. Additionally, public and private sectors' investment in cancer research and drug development significantly boosts market growth.

Another critical growth factor is the technological advancements in biotechnology and pharmaceutical industries. New drug formulations and delivery mechanisms are continually being developed, improving the efficacy and safety profiles of cancer angiogenesis inhibitors. These advancements are not only crucial in enhancing patient outcomes but also in reducing side effects associated with traditional cancer treatments. The advent of personalized medicine and precision oncology is further creating a demand for targeted therapies such as angiogenesis inhibitors.

Government initiatives and favorable reimbursement policies are also playing a crucial role in market expansion. Many countries have recognized the burden of cancer on their healthcare systems and have implemented supportive policies to promote cancer research and drug affordability. Subsidies, grants, and insurance coverage for cancer treatments are making angiogenesis inhibitors more accessible to a broader patient population. Additionally, collaboration between pharmaceutical companies and research institutions is paving the way for novel drug discoveries and market opportunities.

Regionally, North America is expected to dominate the cancer angiogenesis inhibitors market due to its well-established healthcare infrastructure and high healthcare expenditure. The presence of key market players and ongoing clinical trials in this region also contribute to its leading market share. Conversely, the Asia Pacific region is anticipated to witness the highest growth rate during the forecast period, driven by increasing healthcare investments, rising awareness about advanced cancer therapies, and a significant patient pool. Europe, Latin America, and the Middle East & Africa are also projected to experience substantial market growth, supported by improvements in healthcare facilities and growing adoption of advanced cancer treatments.

Drug Type Analysis

The cancer angiogenesis inhibitors market is segmented by drug type into monoclonal antibodies, tyrosine kinase inhibitors, and others. Monoclonal antibodies, such as bevacizumab, are widely used due to their high specificity and effectiveness in targeting angiogenesis pathways. These drugs work by binding to vascular endothelial growth factor (VEGF), preventing it from stimulating the growth of new blood vessels. The market for monoclonal antibodies is robust, driven by their proven clinical efficacy and ongoing development of newer, more effective molecules.

Tyrosine kinase inhibitors (TKIs) represent another significant segment within the cancer angiogenesis inhibitors market. TKIs, such as sunitinib and sorafenib, inhibit the action of tyrosine kinases involved in the signaling pathways that promote angiogenesis. These drugs are particularly effective in treating cancers that have become resistant to other forms of treatment. The TKI market segment is growing rapidly, supported by continuous research and development efforts aimed at enhancing their therapeutic index and reducing adverse effects.

The "Others" category includes a variety of angiogenesis inhibitors that do not fall under monoclonal antibodies or TKIs. This segment comprises novel therapeutic agents and combination therapies that a

Histological subtypes, drug sensitivitiy data and copy number changes of target RTKs in MPM cell lines

Cancer Angiogenesis Inhibitors Market is expected to grow at a high CAGR during the forecast period 2024-2031 | DataM Intelligence

Global Angiogenesis Inhibitors and Stimulators Market size worth over USD 67.17 billion by 2032, at a CAGR of 9.3% during the forecast period.

The market size of the cancer angiogenesis inhibitors market size and forecast is categorized based on Application (Cancer, Interferon Alpha-2, Ocular Neovascularization, Research Methodology) and Product (VEGF Targeted Therapy, FGF Targeted Therapies, Oncogene Targeted Therapy, Matrix Degrading & Remodeling Targeted Therapy) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

The provided report presents market size and predictions for the value of cancer angiogenesis inhibitors market size and forecast, measured in USD million, across the mentioned segments.

Angiogenesis Inhibitors and Stimulators Market Outlook

The angiogenesis inhibitors and stimulators market size is poised for significant growth, with a projected Compound Annual Growth Rate (CAGR) of 8.5% from 2024 to 2032. In 2023, the global market size was valued at approximately USD 15.3 billion, and it is expected to reach USD 32.6 billion by 2032. This robust growth is primarily driven by an increasing prevalence of chronic diseases, advancements in biotechnology, and heightened investment in research and development activities.

One of the most significant growth factors for the angiogenesis inhibitors and stimulators market is the rising incidence of cancer worldwide. As cancer treatment increasingly involves targeted therapies, the demand for angiogenesis inhibitors, which can prevent the formation of new blood vessels that feed tumors, is expected to rise. The development of novel drugs and therapies targeting specific molecular mechanisms related to angiogenesis is also contributing to the market's expansion. Moreover, the growing geriatric population, which is more susceptible to cancer, further fuels this demand.

Another substantial growth driver is the increasing occurrence of cardiovascular diseases (CVDs), which necessitates the use of angiogenesis stimulators. These stimulators promote the growth of new blood vessels, an essential process in treating ischemic heart diseases and peripheral artery disease. With cardiovascular diseases being one of the leading causes of mortality globally, the need for effective treatments that can induce angiogenesis is paramount. Additionally, advancements in regenerative medicine and tissue engineering are further propelling the growth of angiogenesis stimulators in therapeutic applications.

Investment in biotechnology and pharmaceutical research is another critical factor driving market growth. Governments and private entities are increasingly funding research initiatives aimed at understanding the mechanisms of angiogenesis and developing innovative treatments. This surge in investment supports the discovery of new drugs and enhances the efficacy of existing treatments. Furthermore, the regulatory landscape is becoming more favorable, with faster approval processes for breakthrough therapies, thus accelerating market growth.

Regionally, North America is expected to dominate the angiogenesis inhibitors and stimulators market, driven by a well-established healthcare infrastructure, significant investment in research and development, and a high prevalence of cancer and cardiovascular diseases. The presence of major pharmaceutical companies and research institutes in this region also contributes to its market leadership. However, the Asia Pacific region is anticipated to witness the fastest growth, owing to increasing healthcare expenditure, rising awareness about advanced therapies, and a growing patient population.

Product Type Analysis

In the angiogenesis inhibitors and stimulators market, the product type segment is bifurcated into inhibitors and stimulators. Angiogenesis inhibitors are substances that impede the growth of new blood vessels, and they play a crucial role in cancer therapy. These inhibitors help to starve the tumor of the nutrients and oxygen it needs to grow, thereby inhibiting its progression. The development of advanced inhibitors, including monoclonal antibodies and small molecule inhibitors, has significantly improved the efficacy of cancer treatments, making inhibitors a key component of the market.

Angiogenesis stimulators, on the other hand, are vital in the treatment of cardiovascular diseases and wound healing. These stimulators promote the formation of new blood vessels, which can improve blood flow in ischemic tissues and support tissue regeneration. Growth factors like VEGF (Vascular Endothelial Growth Factor) are commonly used as stimulators in various therapeutic applications. The increasing understanding of molecular pathways involved in angiogenesis has led to the development of more targeted and effective stimulators, further driving market growth.

The inhibitors segment is expected to hold a significant share of the market, owing to the high prevalence of cancer and the ongoing development of targeted therapies. With increasing research focused on identifying new molecular targets and understanding resistance mechanisms, the market for angiogenesis inhibito

Abstract: Proteomics has been successfully used for cell culture on dishes, but more complex cellular systems have proven to be challenging and so far poorly approached with proteomics. Because of the complexity of the angiogenic program, we still do not have a complete understanding of the molecular mechanisms involved in this process, and there have been no in depth quantitative proteomic studies. Plating endothelial cells on matrigel recapitulates aspects of vessel growth, and here we investigate this mechanism by using a spike-in SILAC quantitative proteomic approach. By comparing proteomic changes in primary human endothelial cells morphogenesis on matrigel to general adhesion mechanisms in cells spreading on culture dish, we pinpoint pathways and proteins modulated by endothelial cells. The cell-extracellular matrix adhesion proteome depends on the adhesion substrate, and a detailed proteomic profile of the extracellular matrix secreted by endothelial cells identified CLEC14A as a matrix component, which binds to MMRN2. We verify deregulated levels of these proteins during tumor angiogenesis in models of multi-stage carcinogenesis. This is the most in depth quantitative proteomic study of endothelial cell morphogenesis, which shows the potential of applying high accuracy quantitative proteomics to in vitro models of vessel growth to shed new light on mechanisms that accompany pathological angiogenesis. MS data acquisition and analysis: Digested peptides were analyzed by EASY-nLC system (Thermo Fisher Scientific) coupled on line to a LTQ-Orbitrap XL (for the EC morphogenesis and the spreading, and immunoprecipitation studies) or Velos (for the ECM study) (Thermo Fisher Scientific) via a nanoelectrospray ion source (Thermo Fisher Scientific). Chromatographic peptide separation was done in a 15 cm fused silica emitter (Thermo Fisher Scientific) packed in house with reversed-phase Reprosil (Dr. Maisch GmbH) and eluted with a flow of 250 nl/min from 5% to 70% ACN in 0.5% acetic acid, in a 140 min gradient. The full scan MS spectra were acquired with a resolution of 30,000 at m/z 400 in the Orbitrap. The top 5-10 most intense ions were sequentially isolated for fragmentation using CID (for the EC morphogenesis and spreading, and immunoprecipitation studies) or high-energy collision dissociation (for the ECM study), and recorded in the LTQ or Orbitrap, respectively. In the determination of CLEC14A phosphorylation sites, the neutral loss algorithm in the Xcalibur software was enabled for each MS/MS spectrum. Data were acquired with Xcalibur software (Thermo Fisher Scientific). The MS files were processed with the MaxQuant software version 1.2.6.20 and searched with Andromeda search engine against the human UniProt database (release-2012 01, 81,213 entries). To search parent mass and fragment ions, an initial mass deviation of 6 ppm and 0.5 Da (CID) or 20 ppm (HCD), respectively, were required. The minimum peptide length was set to 7 amino acids and strict specificity for trypsin cleavage was required, allowing up to two missed cleavage sites. Carbamidomethylation (Cys) was set as fixed modification, whereas oxidation (Met) and N-acetylation were considered as variable modifications. No labeling or double SILAC labeling was defined accordingly. The false discovery rates (FDRs) at the protein and peptide level were set to 1%. Scores were calculated in MaxQuant as described previously. The reverse and common contaminants hits (in the ECM proteome analysis, KRT1 and KRT9 were additionally included), were removed from MaxQuant output. Only proteins identified with at least one peptide uniquely assigned to the respective sequence were considered for the analysis. For SILAC protein quantification, the re-quantification feature was enabled, and the relative quantification of the peptides against their SILAC-labeled counterparts was performed by MaxQuant. Only unique peptides were used for quantification and we required proteins being quantified with at least two ratio counts. For the immunoprecipitation and ECM analyses, proteins were quantified according to the MaxQuant label-free algorithm; unique and razor (=most likely belonging to the protein group) peptides were used for protein quantification.

Angiogenesis Assay Market Analysis

The Angiogenesis Assay Market is experiencing significant growth, according to...

CCR Translation for the Article from Ambulatory Monitoring Detects Sorafenib-Induced Blood Pressure Elevations on the First Day of Treatment

The market size of the Angiogenesis Assay Market is categorized based on Type (In Vitro Assay Kit, In Vivo Assay Kit) and Application (Academic Institution, Biotech Companies) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

The provided report presents market size and predictions for the value of Angiogenesis Assay Market, measured in USD million, across the mentioned segments.

Osteosarcoma (OS) is the most common primary bone tumor mainly occurring in young adults and derived from primitive bone-forming mesenchyme. OS develops in an intricate tumor microenvironment (TME) where cellular function regulated by microRNAs (miRNAs) may affect communication between OS cells and the surrounding TME. Therefore, miRNAs are considered potential therapeutic targets in cancer and one of the goals of research is to accurately define a specific signature of a miRNAs, which could reflect the phenotype of a particular tumor, such as OS. Through NGS approach, we previously found a specific molecular profile of miRNAs in OS and discovered 8 novel miRNAs. Among these, we deepen our knowledge on the fifth candidate renamed now miR-CT3. MiR-CT3 expression was low in OS cells when compared with human primary osteoblasts and healthy bone. Through TargetScan, VEGF-A was predicted as a potential biological target of miR-CT3 and luciferase assay confirmed it. We showed that enforced expression of miR-CT3 in two OS cell lines, SAOS-2 and MG-63, reduced expression of VEGF-A mRNA and protein, inhibiting tumor angiogenesis. Enforced expression of miR-CT3 also reduced OS cell migration and invasion as confirmed by soft agar colony formation assay. Interestingly, we found that miR-CT3 behaves inducing the activation of p38 MAP kinase pathway and modulating the epithelial-mesenchymal transition (EMT) proteins, in particular reducing Vimentin expression. Overall, our study highlights the novel role of miR-CT3 in regulating tumor angiogenesis and progression in OS cells, linking also to the modulation of EMT proteins.

The Angiogenesis Inhibitors and Stimulators Market is projected to surge from USD 27,604.64 million in 2024 to USD 58,148.01 million by 2032, representing a robust CAGR of 9.76%.

Excel spread sheet of data used to construct graphs in 'Adjusting the Physico-Chemical Properties of Collagen Scaffolds to Accommodate Primary Osteoblasts and Endothelial Cells' that has been published in Regenerative Biomaterials

Epithelial network.Regulatory network for PDAC-associated epithelial cells, listing the inferred transcriptional targets (Target) for each regulatory protein (Regulator). Association weight (AW) and association mode (AM) are scores to quantify strength/direction of interaction. Sign indicates directionality of the interaction (1 = transactivating, -1 = transrepressing).

A new class of 2-anilino-3-cyanobenzo[b]thiophenes (2,3-ACBTs) was studied for its antiangiogenic activity for the first time. One of the 2,3-ACBTs inhibited tubulogenesis in a dose-dependent manner without any toxicity. The 2,3-ACBTs significantly reduced neovascularization in both ex vivo and in vivo angiogenic assays without affecting the proliferation of endothelial cells. Neovascularization was limited through reduced phosphorylation of Akt/Src and depolymerization of f-actin and β-tubulin filaments, resulting in reduced migration of cells. In addition, the 2,3-ACBT compound disrupted the preformed angiogenic tubules, and docking/competitive binding studies showed that it binds to VEGFR2. Compound 2,3-ACBT had good stability and intramuscular profile, translating in suppressing the tumor angiogenesis induced in a xenograft model. Overall, the present study suggests that 2,3-ACBT arrests angiogenesis by regulating the Akt/Src signaling pathway and deranging cytoskeletal filaments of endothelial cells.

The market size of the Angiogenesis Modulators Market is categorized based on Application (Inhibitors, Stimulators, Endogenous Factors, Exogenous Factors, Combination Therapy) and Product (Cancer Treatment, Wound Healing, Cardiovascular Diseases, Diabetic Retinopathy, Age-related Macular Degeneration) and geographical regions (North America, Europe, Asia-Pacific, South America, and Middle-East and Africa).

The provided report presents market size and predictions for the value of Angiogenesis Modulators Market, measured in USD million, across the mentioned segments.

Angiogenesis, the process by which new blood vessels are recruited to existing ones, is essential for tumor development. Insulin-like growth factor (IGF) binding protein-3 (IGFBP-3), which modulates bioavailability of IGF, has been studied for its potential role in angiogenesis during tissue regeneration and cancer development. In this study, we assessed the role of IGFBP-3 in tumor angiogenesis in head and neck squamous cell carcinoma (HNSCC) and human umbilical vein endothelial cells (HUVECs) using adenoviral (Ad-BP3) and recombinant (rBP3) IGFBP-3. Using an in vivo orthotopic tongue tumor model, we confirmed that both Ad-BP3 and rBP3 suppress the growth of UMSCC38 HNSCC cells in vivo. Ad-BP3 inhibited vascularization in tongue tumors and chorio-allantoic membrane, and suppressed angiogenesis-stimulating activities in UMSCC38 cells. In HUVECs, Ad-BP3 decreased migration, invasion, and tube formation. rBP3 also suppressed production of vascular endothelial growth factor (VEGF) in HUVECs and UMSCC38 cells. IGFBP-3-GGG, a mutant IGFBP-3 with loss of IGF binding capacity, suppressed VEGF production. In addition, we found that IGFBP-3 suppressed VEGF expression, even in mouse embryonic fibroblasts from an IGF-1R-null mouse. Finally, we demonstrated that IGFBP-3-GGG inhibits tumor angiogenesis and growth to the same degree as wild-type IGFBP-3. Taken together, these results support the hypothesis that IGFBP-3 has anti-angiogenic activity in HNSCC, at least in part due to IGF-independent suppression of VEGF production from vascular endothelial cells and cancer cells.

Lymphoid network.Regulatory network for PDAC-associated lymphoid cells, listing the inferred transcriptional targets (Target) for each regulatory protein (Regulator). Association weight (AW) and association mode (AM) are scores to quantify strength/direction of interaction. Sign indicates directionality of the interaction (1 = transactivating, -1 = transrepressing).